Gustavo A. Rosario Benitez

Array ( [id] => 9107142 [patent_doc_number] => 20130280274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-24 [patent_title] => 'METHODS TO MODULATE LYSINE VARIANT DISTRIBUTION' [patent_app_type] => utility [patent_app_number] => 13/830976 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 28686 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13830976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9081030 [patent_doc_number] => 20130266560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-10-10 [patent_title] => 'Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation' [patent_app_type] => utility [patent_app_number] => 13/830831 [patent_app_country] => US [patent_app_date] => 2013-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 82704 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13830831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281663 [patent_doc_number] => 20150166660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'IMMUNOMODULATION BY ANTI-CD3 IMMUNOTOXINS TO TREAT CANCERS NOT UNIFORMLY BEARING SURFACE CD3' [patent_app_type] => utility [patent_app_number] => 14/390885 [patent_app_country] => US [patent_app_date] => 2013-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6570 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9435036 [patent_doc_number] => 20140112942 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'AGONISTIC ANTIBODY TO CD27' [patent_app_type] => utility [patent_app_number] => 13/792425 [patent_app_country] => US [patent_app_date] => 2013-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17776 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13792425 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330091 [patent_doc_number] => 20140056873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation' [patent_app_type] => utility [patent_app_number] => 13/790756 [patent_app_country] => US [patent_app_date] => 2013-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 72 [patent_figures_cnt] => 72 [patent_no_of_words] => 98570 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13790756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9857318 [patent_doc_number] => 20150037334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-05 [patent_title] => 'LONG LIFE POLYPEPTIDE BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/381902 [patent_app_country] => US [patent_app_date] => 2013-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 29546 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14381902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12044587 [patent_doc_number] => 09822180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'Immunotherapeutic molecules and uses' [patent_app_type] => utility [patent_app_number] => 14/381405 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 10 [patent_no_of_words] => 35385 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 239 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14381405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9798637 [patent_doc_number] => 20150010581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'COMBINED THERAPY OF ALPHA-1-ANTITRYPSIN AND TEMPORAL T-CELL DEPLETION FOR PREVENTING GRAFT REJECTION' [patent_app_type] => utility [patent_app_number] => 14/380118 [patent_app_country] => US [patent_app_date] => 2013-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9211 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14380118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989841 [patent_doc_number] => 20130217122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library' [patent_app_type] => utility [patent_app_number] => 13/773090 [patent_app_country] => US [patent_app_date] => 2013-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 19570 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13773090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10280009 [patent_doc_number] => 20150165006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED ALLERGENIC ANTIGEN OR AN AUTOIMMUNE SELF-ANTIGEN' [patent_app_type] => utility [patent_app_number] => 14/378591 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 44658 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14378591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9490689 [patent_doc_number] => 20140141093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/763768 [patent_app_country] => US [patent_app_date] => 2013-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 95 [patent_figures_cnt] => 95 [patent_no_of_words] => 57193 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13763768 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989248 [patent_doc_number] => 20130216530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants' [patent_app_type] => utility [patent_app_number] => 13/756616 [patent_app_country] => US [patent_app_date] => 2013-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 6226 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13756616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13220571 [patent_doc_number] => 10124046 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-13 [patent_title] => HLA-DR-binding antigen peptide derived from WT1 [patent_app_type] => utility [patent_app_number] => 13/755185 [patent_app_country] => US [patent_app_date] => 2013-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 15001 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13755185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10498572 [patent_doc_number] => 09226962 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-01-05 [patent_title] => 'Human CD3-specific antibody with immunosuppressive properties' [patent_app_type] => utility [patent_app_number] => 13/739736 [patent_app_country] => US [patent_app_date] => 2013-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 8195 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13739736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9222920 [patent_doc_number] => 20140017695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-16 [patent_title] => 'ISOLATING CELLS EXPRESSING SECRETED PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/738349 [patent_app_country] => US [patent_app_date] => 2013-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 16627 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13738349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8814171 [patent_doc_number] => 20130115217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'ANTIBODIES AGAINST HMGB1 AND FRAGMENTS THEREOF' [patent_app_type] => utility [patent_app_number] => 13/736250 [patent_app_country] => US [patent_app_date] => 2013-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 14542 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13736250 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8989257 [patent_doc_number] => 20130216538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-22 [patent_title] => 'Compositions and Methods for Treating Inflammatory Disorders' [patent_app_type] => utility [patent_app_number] => 13/733675 [patent_app_country] => US [patent_app_date] => 2013-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 90170 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13733675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11790107 [patent_doc_number] => 09399679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-26 [patent_title] => 'Therapeutic anti-TIRC7 antibodies for use in immune related and other diseases' [patent_app_type] => utility [patent_app_number] => 13/725535 [patent_app_country] => US [patent_app_date] => 2012-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 12356 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13725535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11343520 [patent_doc_number] => 09527916 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Agonistic antibody to CD27' [patent_app_type] => utility [patent_app_number] => 13/719723 [patent_app_country] => US [patent_app_date] => 2012-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 17772 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13719723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944745 [patent_doc_number] => 10208131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Artificially produced polyclonal immunoglobulin preparation [patent_app_type] => utility [patent_app_number] => 13/716469 [patent_app_country] => US [patent_app_date] => 2012-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 5859 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13716469 [rel_patent_id] =>[rel_patent_doc_number] =>)